---
title: Daratumumab Carfilzomib Lenalidomide and Dexamethasone with tandem transplant
  in high-risk newly diagnosed myeloma
date: '2024-02-23'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38394666/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20240224170823&v=2.18.0.post9+e462414
source: Blood
description: High-risk (HR) cytogenetics are associated with poor outcomes in newly
  diagnosed multiple myeloma (NDMM) and dedicated studies should address this difficult-to-treat
  population. The phase 2 study 2018-04 from the Intergroupe Francophone du Myelome
  evaluated feasibility of an intensive strategy with quadruplet induction and consolidation
  plus tandem transplant in HR transplant eligible (TE) NDMM (NCT03606577). HR cytogenetics
  were defined by the presence of del(17p), t(4;14) and/or ...
disable_comments: true
---
High-risk (HR) cytogenetics are associated with poor outcomes in newly diagnosed multiple myeloma (NDMM) and dedicated studies should address this difficult-to-treat population. The phase 2 study 2018-04 from the Intergroupe Francophone du Myelome evaluated feasibility of an intensive strategy with quadruplet induction and consolidation plus tandem transplant in HR transplant eligible (TE) NDMM (NCT03606577). HR cytogenetics were defined by the presence of del(17p), t(4;14) and/or ...